Literature DB >> 10193665

Pharmacological profile of neuroleptics at human monoamine transporters.

M Tatsumi1, K Jansen, R D Blakely, E Richelson.   

Abstract

Using radioligand binding techniques, we determined the equilibrium dissociation constants (K(D)) for 37 neuroleptics and one metabolite of a neuroleptic (haloperidol metabolite) for the human serotonin, norepinephrine, and dopamine transporters with [3H]imipramine, [3H]nisoxetine, and [3H]WIN35428, respectively. Among neuroleptics, the four most potent compounds at the human serotonin transporter were triflupromazine, fluperlapine, chlorpromazine, and ziprasidone (K(D) 24-39 nM); and at the norepinephrine transporter, chlorpromazine, zotepine, chlorprothixene, and promazine (K(D) 19-25 nM). At the human dopamine transporter, only pimozide (K(D) = 69+/-3) ziprasidone (K(D) = 76+/-5) had notable potency. These data may be useful in predicting therapeutic and adverse effects, including drug interactions of neuroleptics.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10193665     DOI: 10.1016/s0014-2999(99)00005-9

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  19 in total

1.  The lack of effect of ziprasidone on platelet serotonin concentration in schizophrenic patients.

Authors:  Marina Sagud; Matea Nikolac; Alma Mihaljevic-Peles; Gordana Nedic; Bjanka Vuksan Cusa; Maja Mustapic; Miro Jakovljevic; Dorotea Muck-Seler; Nela Pivac
Journal:  Psychopharmacology (Berl)       Date:  2011-10-12       Impact factor: 4.530

Review 2.  Antipsychotic and antidepressive effects of second generation antipsychotics: two different pharmacological mechanisms?

Authors:  Hans-Jürgen Möller
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2005-06       Impact factor: 5.270

Review 3.  Clinical Pharmacokinetics of Atypical Antipsychotics: An Update.

Authors:  Massimo Carlo Mauri; Silvia Paletta; Chiara Di Pace; Alessandra Reggiori; Giovanna Cirnigliaro; Isabel Valli; Alfredo Carlo Altamura
Journal:  Clin Pharmacokinet       Date:  2018-12       Impact factor: 6.447

4.  Interaction of antidepressant and antipsychotic drugs with the human organic cation transporters hOCT1, hOCT2 and hOCT3.

Authors:  Britta Haenisch; Eva Drescher; Lidia Thiemer; Hu Xin; Bruno Giros; Sophie Gautron; Heinz Bönisch
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-07-18       Impact factor: 3.000

5.  Sertraline delays relapse in recently abstinent cocaine-dependent patients with depressive symptoms.

Authors:  Alison Oliveto; James Poling; Michael J Mancino; D Keith Williams; Jeff Thostenson; Rhonda Pruzinsky; Kishorchandra Gonsai; Mehmet Sofuoglu; Gerardo Gonzalez; Shanti Tripathi; Thomas R Kosten
Journal:  Addiction       Date:  2011-10-10       Impact factor: 6.526

6.  Contribution of the active metabolite M1 to the pharmacological activity of tesofensine in vivo: a pharmacokinetic-pharmacodynamic modelling approach.

Authors:  T Lehr; A Staab; C Tillmann; E Ø Nielsen; D Trommeshauser; H G Schaefer; C Kloft
Journal:  Br J Pharmacol       Date:  2007-11-05       Impact factor: 8.739

7.  Membrane glycoprotein M6B interacts with the human serotonin transporter.

Authors:  Anja Winther Fjorback; Heidi Kaastrup Müller; Ove Wiborg
Journal:  J Mol Neurosci       Date:  2008-06-26       Impact factor: 3.444

8.  Zotepine for behavioural and psychological symptoms in dementia: an open-label study.

Authors:  Michael K Rainer; Hermann A M Mucke; Christine Krüger-Rainer; Manfred Haushofer; Sigfried Kasper
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

Review 9.  Ziprasidone for the treatment of acute manic or mixed episodes associated with bipolar disorder.

Authors:  Lewis Warrington; Ilise Lombardo; Antony Loebel; Kathleen Ice
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

Review 10.  Dopamine transporter imaging with [(123)I]FP-CIT SPECT: potential effects of drugs.

Authors:  Jan Booij; Paul Kemp
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-10-30       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.